Search | Clinical Trials Finder

Conditions: Colitis Ulcerative
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 27
States / cities: Apple Valley, California • Beverly Hills, California • Oxnard, California + 24 more

Conditions: Diabetes Mellitus, Type 1
Interventions: insulin, human insulin inhalation powder (HIIP); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 25
States / cities: San Diego, California • Denver, Colorado • Hollywood, Florida + 22 more

Conditions: Perfusion; Complications
Interventions: micro dosing of ICG; Other
Lead sponsor: Shanglei Liu; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Influenza, Respiratory Tract Infections
Interventions: Enhanced texts with Callback by a Person, Enhanced Bidirectional Texts; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 6 Months and older
Enrollment: 246,295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions: Canakinumab 150 mg, Placebo to Canakinumab; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 11
States / cities: Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more

Conditions: Diabetes Mellitus
Interventions: Lantus (insulin glargine [rDNA origin] injection), Humulin N, Humulin L, Lispro; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 9 Years to 17 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2002
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Head and Neck Cancer
Interventions: [18F]- PARPi, PET/CT Scans; Drug · Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Bronchopulmonary Dysplasia
Interventions: Chest computed tomography (CT) with angiography, Bronchoscopy with bronchoalveolar lavage, Echocardiography, 24 hour esophageal pH ("potential of hydrogen") - multichannel intraluminal impedance (MII) monitoring (reflux testing); Diagnostic Test
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 1 Month to 1 Year
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetic Maculopathy
Interventions: Spironolactone 50 mg; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 20 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Diabetes Mellitus, Type 1, Insulin-dependent Diabetes Mellitus
Interventions: PRAM9, Regular Insulin + Pramlintide, Regular Insulin; Drug
Lead sponsor: Xeris Pharmaceuticals; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Fever of Unknown Origin
Interventions: 68Ga-Citrate PET/MRI, 67Ga-Citrate SPECT, Positron Emission Tomography, Magnetic Resonance Imaging, SPECT; Drug · Device
Lead sponsor: Carina Mari Aparici; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Obese
Interventions: Semaglutide Injectable Product (Wegovy and/or Ozempic); Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Years to 35 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Lymphoma, Mantle-Cell
Interventions: CpG-MCL vaccine, PF-3512676, Vaccine-primed T-cells, Autologous hematopoietic stem cell transplant (HSCT), Rituximab, Standard induction chemotherapy, Cyclophosphamide, Filgrastim; Biological · Procedure · Drug
Lead sponsor: Ronald Levy; Other
Eligibility: 21 Years to 70 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Postoperative Pain
Interventions: Exparel, Bupivacaine hydrochloride, Patient Controlled Analgesia (PCA); Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes
Interventions: Wosulin R, Actrapid; Biological
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Brain Mapping
Interventions: Brain connectivity and physiology, Brain Wave; Other
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hemophilia
Interventions: Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC); Drug · Biological
Lead sponsor: Sanofi; Industry
Eligibility: 1 Year to 11 Years · Male only
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 5
States / cities: Los Angeles, California • Orange, California • Las Vegas, Nevada + 2 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20); Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Milk Allergy
Interventions: Placebo for omalizumab, Omalizumab, Milk powder; Biological · Drug
Lead sponsor: Hugh A Sampson, MD; Other
Eligibility: 7 Years to 35 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 3
States / cities: Stanford, California • Baltimore, Maryland • New York, New York

Conditions: Metabolism of Prostaglandin D2
Interventions: niacin, aspirin, PGD2; Dietary Supplement · Drug · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Diabetes Mellitus, Type 1
Interventions: Insulin Lispro, regular human insulin, recombinant human hyaluronidase PH20, Insulin glargine; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 8
States / cities: Aurora, Colorado • Miami, Florida • Detroit, Michigan + 5 more

Conditions: Kidney Transplantation, Diabetes, Hyperglycemia
Interventions: insulin, NPH Insulin or glargine insulin and aspartame insulin; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Colorectal Neoplasms, Breast Neoplasms, Head and Neck Neoplasms, Gastro-Intestinal Intraepithelial Neoplasia
Interventions: Fluorouracil injection, Xeloda; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 12
States / cities: Belleville, New Jersey • Elizabeth, New Jersey • Hamilton, New Jersey + 6 more

Conditions: Cold Urticaria
Interventions: Dupilumab SAR231893, Placebo, Non sedating H1-antihistamine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 5
States / cities: San Diego, California • Boise, Idaho • Owensboro, Kentucky + 2 more

Search by objective public record fields.

A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))

Safety and Efficacy of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes Mellitus.

Microdosing ICG for Serial Colonic Perfusion Study During Surgery

Patient Portal Flu Vaccine Reminders_RCT 5 (LADHS)

To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies

Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents

Imaging With a PET Agent for Detection of Cancers of the Head and Neck

Multidimensional Phenotype Classification in Grade 3 Bronchopulmonary Dysplasia

Non-Responsive Diabetic Macular Edema and Spironolactone

Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D

68Ga Citrate PET/MRI for Evaluation of Fever of Unknown Origin (FUO)

Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome

Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL

PAIN - Postoperative Analgesia INvestigation

Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Type 1 Diabetics

Human Brain Mapping of the Apparent Diffusion Coefficient (ADC) During Sleep and Wakefulness

A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)

OIT and Xolair® (Omalizumab) in Cow's Milk Allergy

Pathways of Eicosanoid Metabolism

Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus

IV Insulin Protocol in Diabetes and Renal Transplantation

DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment

Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)